Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarloxotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-08 |
| ALK/TRK Inhibitor TSR-011 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-10 |
| AZD-4547 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-04 |
| Ningetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 5, 2019 |
| PD-1 Ligand Inhibitor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 13, 2024 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.